ijms-logo

Journal Browser

Journal Browser

State-of-the-Art Molecular Pharmacology in France

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 3096

Special Issue Editors


E-Mail Website
Collection Editor
Lab of Biomolecules, Sorbonne Universite, Paris, France
Interests: molecular modeling; molecular pharmacology; drug development

E-Mail Website
Collection Editor
Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Institut Régional du Cancer de Montpellier, Université de Montpellier, F-34298 Montpellier, France
Interests: drug resistance; chemotherapy; DNA topoisomerases; DNA damage; prostate cancer; colon cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Pharmacology is a discipline that deals with the interactions between natural, semisynthetic, or fully (bio)synthetic therapeutic agents at the cellular and organismal levels. These therapeutic agents can be small molecules or macromolecules, such as proteins and antibodies. Thus, this subject is positioned at the interface of pharmacy/chemistry and physiology/pathophysiology in their broadest senses. It operates at various organizational levels, such as the molecular, subcellular, cellular, organ, and systemic platforms. Molecular pharmacology investigates the molecular mode of action of therapeutic agents using cellular, genetic, and molecular biology approaches and is among the most rapidly developing fields of pharmacology.

Original research and review articles on molecular pharmacology are invited. The Section “Molecular Pharmacology” aims to publish the latest developments in cellular and molecular pharmacology with a major emphasis on the mechanism of action of novel drugs, innovative pharmacological technologies, cell signaling, transduction pathway analysis, genomics, proteomics, and metabonomics applications to study drug action. An additional focus will be on the way in which normal biological function is illuminated by knowledge of the action of drugs at the cellular and molecular level.

A great number of research teams in France from different institutions and universities are working together and devoting considerable effort to developing and studying molecular pharmacology. This Topical Collection is committed to providing an overview of the macromolecular sciences and technologies in France.

Dr. Nicolas Pietrancosta
Prof. Dr. Philippe Pourquier
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • signal transduction
  • receptor
  • animal models
  • preclinical
  • pharmacodynamics
  • pharmacokinetics
  • drug development
  • drug metabolism

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

25 pages, 3300 KiB  
Article
The Unitary Micro-Immunotherapy Medicine Interferon-γ (4 CH) Displays Similar Immunostimulatory and Immunomodulatory Effects than Those of Biologically Active Human Interferon-γ on Various Cell Types
by Camille Jacques, Mathias Chatelais, Karim Fekir, Adrien Brulefert and Ilaria Floris
Int. J. Mol. Sci. 2022, 23(4), 2314; https://doi.org/10.3390/ijms23042314 - 19 Feb 2022
Cited by 9 | Viewed by 2669
Abstract
As a cytokine, gamma-interferon (IFN-γ) is considered a key player in the fine-tuned orchestration of immune responses. The extreme cellular sensitivity to cytokines is attested by the fact that very few of these bioactive molecules per cell are enough to trigger cellular functions. [...] Read more.
As a cytokine, gamma-interferon (IFN-γ) is considered a key player in the fine-tuned orchestration of immune responses. The extreme cellular sensitivity to cytokines is attested by the fact that very few of these bioactive molecules per cell are enough to trigger cellular functions. These findings can, at least partially, explain how/why homeopathically-prepared cytokines, and especially micro-immunotherapy (MI) medicines, are able to drive cellular responses. We focused our fundamental research on a unitary MI preparation of IFN-γ, specifically employed at 4 CH, manufactured and impregnated onto sucrose-lactose pillules as all other MI medicines. We assessed the IFN-γ concentration in the medium after dilution of the IFN-γ (4 CH)-bearing pillules and we evaluated in vitro drug responses in a wide range of immune cells, and in endothelial cells. Our results showed that IFN-γ (4 CH) stimulated the proliferation, the activation and the phagocytic capabilities of primary immune cells, as well as modulated their cytokine-secretion and immunity-related markers’ expression in a trend that is quite comparable with the well-recognized biological effects induced by IFN-γ. Altogether, these data provide novel and additional evidences on MI medicines, and specifically when active substances are prepared at 4 CH, thus suggesting the need for more investigations. Full article
(This article belongs to the Special Issue State-of-the-Art Molecular Pharmacology in France)
Show Figures

Figure 1

Back to TopTop